Annual report pursuant to Section 13 and 15(d)

Segment Information (Schedule of Segment Information) (Details)

v3.24.1
Segment Information (Schedule of Segment Information) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]    
Net Revenue $ 84,513 $ 75,743
Cost of goods - product revenue (26,660) (30,775)
Research and development (106,071) (134,876)
Selling, general and administrative (94,124) (113,656)
Asset impairment (3,100)  
Other expense (11,291) (9,900)
Income tax expense (521) (449)
Net loss (154,154) (213,913)
Dermatology Products Sales    
Segment Reporting Information [Line Items]    
Net Revenue 79,181 73,669
Cost of goods - product revenue (26,660) (30,775)
Research and development (7,541) (10,943)
Selling, general and administrative (47,053) (59,503)
Other expense (1,559) (2,048)
Income tax expense (221)  
Net loss (3,853) (29,600)
Pharmaceutical and Biotechnology Product Development    
Segment Reporting Information [Line Items]    
Net Revenue 5,332 2,074
Cost of goods - product revenue 0 0
Research and development (98,530) (123,933)
Selling, general and administrative (47,071) (54,153)
Other expense (9,732) (7,852)
Income tax expense (300) (449)
Net loss $ (150,301) $ (184,313)